Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03049423 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-03049423 | ACTIVE_COMPARATOR | Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers |
| Drug | PLACEBO_COMPARATOR | Placebo in oral solution, given once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| PF-03049423 | DRUG | PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers |
| Placebo | DRUG | Placebo in oral solution, given once daily for 14 days |
Inclusion Criteria: * Healthy persons, male or female. * For the healthy young adult cohort, subjects must be 18 to 50 years old, inclusive. * For the healthy elderly adult cohort, subjects must be 51 to 99 years old, inclusive. * Body Mass Index (BMI) of 18 to 35; and a total body weight \>50 kg (...
PF-03049423 is an investigational small molecule being studied for use in healthy adults and healthy older volunteers. It is currently in Phase 1 clinical development, and its safety and tolerability are being evaluated in this population.
PF-03049423 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange.
PF-03049423 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
PF-03049423 has one completed clinical trial, identified as NCT01161069. This Phase 1 study evaluated the safety and tolerability of different doses of PF-03049423 in healthy adult volunteers and healthy older volunteers in Belgium.
No alternative names for PF-03049423 have been disclosed. It is identified by its compound number, PF-03049423, in clinical trial records.